Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

TAK-901

Catalog No: tcsc0243

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
934541-31-8

Formula:
$C_{28}H_{32}N_4O_3S$

Pathway:
Cell Cycle/DNA Damage;Epigenetics

Target:
Aurora Kinase;Aurora Kinase

Purity / Grade:
>98%

Solubility:
DMSO : 2 mg/mL (3.96 mM; Need ultrasonic and warming)

Observed Molecular Weight:
504.64

Product Description

TAK-901 is a multi-targeted **aurora** inhibitor with **IC_{50}**s of 21 and 15 nM for aurora A and B, respectively.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: IC50: 21 nM (aurora A), 15 nM (aurora B), 1.2 nM (JAK3), 1.3 nM (Src), 2 nM (FGR), 5 nM (FLT3)[1]

In Vitro: TAK-901 exhibits time-dependent, tight-binding inhibition of Aurora B, but not Aurora A. Consistent with Aurora B inhibition, TAK-901 suppresses cellular histone H3 phosphorylation and induces polyploidy. In various human cancer cell lines, TAK-901inhibits cell proliferation with effective concentration values from 40 to 500 nM. Examination of a broad panel of kinases in biochemical assays reveals inhibition of multiple kinases. However, TAK-901 potently inhibits only a few kinases other than Aurora B in intact cells, including FLT3 and FGFR2[1].

In Vivo: In rodent xenografts, TAK-901 exhibits potent activity against multiple human solid tumor types, and complete regression is observed in the ovarian cancer A2780 model. TAK-901 also displayed potent activity against several leukemia models. TAK-901 induces pharmacodynamic responses consistent with Aurora B inhibition and correlating with retention of TAK-901 in tumor tissue[1].